

Sangamo Therapeutics Logo

## Sangamo BioSciences Announces Presentation At The Cowen And Company 36th Annual Health Care Conference

March 1, 2016

RICHMOND, Calif., March 1, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic<sup>®</sup> development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 9, 2016, at the Cowen and Company 36<sup>th</sup> Annual Health Care Conference. The conference is being held in Boston from March 7-9, 2016.



The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under [Events and Presentation](#). The presentation will be archived on the Sangamo website for two weeks after the event.

### About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures<sup>®</sup> for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform<sup>™</sup> (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B, the first *in vivo* genome editing application cleared by the FDA, and MPS I. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics<sup>®</sup> for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at [www.sangamo.com](http://www.sangamo.com).

*ZFP Therapeutic<sup>®</sup> is a registered trademark of Sangamo BioSciences, Inc.*

Logo - <https://photos.prnewswire.com/prnh/20130102/SF35903LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-presentation-at-the-cowen-and-company-36th-annual-health-care-conference-300228852.html>

SOURCE Sangamo BioSciences, Inc.

Released March 1, 2016